ProCE Banner Activity

Key Takeaways in the Management of HER2-Negative Early Breast Cancer: Focus on Treating Patients With Pathogenic Variants in Germline BRCA

Clinical Thought

Expert pharmacists highlight key points in the management of patients with HER2-negative early breast cancer, with a focus on treating patients with pathogenic variants in germline BRCA.

Released: May 17, 2024

Expiration: May 16, 2025

Share

Faculty

Allison Butts

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
UK Healthcare
Lexington, Kentucky

Jordan Hill

Jordan Hill, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
West Virginia University Cancer Institute
Morgantown, West Virginia

Provided by

Provided by ProCE, LLC, in partnership with Clinical Care Options

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.

AstraZeneca

Merck Sharp & Dohme, LLC

Partners

Clinical Care Options, LLC

ProCE Banner

Disclosure

Primary Author

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
UK Healthcare
Lexington, Kentucky

Allison Butts, PharmD, BCOP, has no relevant financial relationships to disclose.

Jordan Hill, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
West Virginia University Cancer Institute
Morgantown, West Virginia

Jordan Hill, PharmD, BCOP, has no relevant financial relationships to disclose.